Medicines watchdog approves two treatments for patients with spinal muscular atrophy
Hundreds of children with a rare muscle-wasting disease will be able to receive two drugs that can improve their survival in a move parents hailed as a “lifeline”.
The National Institute for Health and Care Excellence (Nice) has published final draft guidance recommending that any patient who would benefit can have either drug.
Continue reading...
TH
Source
This article was originally published by The Guardian and written by Denis Campbell Health policy editor.
Read original article on The Guardian